Edition:
United Kingdom

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

27.97USD
17 Aug 2018
Change (% chg)

$0.07 (+0.25%)
Prev Close
$27.90
Open
$27.79
Day's High
$28.07
Day's Low
$27.35
Volume
226,553
Avg. Vol
154,458
52-wk High
$41.75
52-wk Low
$18.75

Select another date:

Tue, May 8 2018

BRIEF-Aimmune Therapeutics Reports Q1 Loss Per Share $0.92

* AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Aimmune Therapeutics Qtrly Loss Per Share $0.81

* AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock

* AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Aimmune's peanut allergy drug meets main goal, shares surge

U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

UPDATE 2-Aimmune's peanut allergy drug meets main goal, shares surge

Feb 20 U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy

* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY

Aimmune's peanut allergy drug meets main goal of key study

Feb 20 U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Select another date: